Amgen — Nov 4, 2025 release

pts: percentage points * = Change in excess of 100% N/A = not applicable Cash Flow and Balance Sheet • The Company generated $4.2 billion of free cash flow in the third quarter of 2025 versus $3.3 billion in the third quarter of 2024, driven by the timing of working capital items and lower interest payments, partially offset by higher capital expenditures. • The Company declared a third quarter 2025 dividend on August 1, 2025 of $2.38 per share that was paid on September 12, 2025 to all stockholders of record as of August 22, 2025, representing a 6% increase from the same period in 2024. • The Company retired $1.6 billion of debt during the third quarter of 2025 and $6.0 billion year to date. • During the third quarter of 2025, there were no repurchases of shares of common stock under our stock repurchase program. • Cash and cash equivalents totaled $9.4 billion and debt outstanding totaled $54.6 billion as of September 30, 2025. $Billions, except shares Q3 ’25 Q3 ’24 YOY Δ Operating Cash Flow $ 4.7  $ 3.6  $ 1.1  Capital Expenditures $ 0.4  $ 0.3  $ 0.2  Free Cash Flow $ 4.2  $ 3.3  $ 0.9  Dividends Paid $ 1.3  $ 1.2  $ 0.1  Share Repurchases $ 0.0  $ 0.0  $ 0.0  Average Diluted Shares (millions) 542  542  0  Note: Numbers may not add due to rounding AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Page 7 $Billions 9/30/25 12/31/24 YTD Δ Cash and Cash Equivalents $ 9.4  $ 12.0  $ (2.5) Debt Outstanding $ 54.6  $ 60.1  $ (5.5) Note: Numbers may not add due to rounding 2025 Guidance For the full year 2025, the Company expects: • Total revenues in the range of $35.8 billion to $36.6 billion. • On a GAAP basis, EPS in the